[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jacob Bodilsen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100573775","the-impact-of-de-implementing-urine-dipsticks-for-diagnosis-of-utis-in-hospitals-100573775",false,"NCT06750666","The Impact of De-implementing Urine Dipsticks for Diagnosis of UTIs in Hospitals","The Impact of De-implementing Urine Dipsticks for Diagnosis of Urinary Tract Infections in the North Denmark Region: An Interrupted Time-series Analysis","Inclusion Criteria:\n\n* All patients admitted to emergency rooms (≥18 years) from 2019 and forward.\n\nExclusion Criteria:\n\n* Patients directly admitted to an inpatient unit without first visiting an emergency room are excluded from the study.\n* For the primary analysis, only the first admission will be included; subsequent admissions will be excluded.","ALL","18 Years",{"count":19,"type":20},480000,"ESTIMATED","30 Days","OBSERVATIONAL","The goal of this interrupted time-series analysis is to evaluate the impact of the de-implementation of urine dipsticks as a diagnostic tool for urinary tract infections (UTIs) in hospitalized patients in the North Denmark Region. The main question it aims to answer is:\n\nHow does de-implementation of urine dipsticks affect the diagnosis and management of UTIs and related disorders?\n\nSpecifically, does it change the following parameters:\n\n* Number and severity of UTI infections (lower and upper UTI, non-severe and severe)\n* Antibiotic prescription (overall, antibiotic classes, administration routes, duration, dosages)\n* Number of urine cultures and number of positive urine cultures\n* Risks of admission to intensive care units and 30-day mortality\n* Risk of drug toxicity\n* Length of hospital stay\n* Risk of admission to intensive care unit\n* 30-day risk of readmission after discharge\n* 6-month risks of Clostridioides difficile enterocolitis and de novo antimicrobial resistance in cultures obtained during routine clinical care.\n\nResearchers hypothesize that de-implementing urine dipsticks will lead to a reduced frequency of diagnosed cystitis, reduced antibiotic use, and fewer urine cultures without negatively affecting patient mortality or readmission risk.\n\nResearchers will compare the outcomes before and after the discontinuation of urine dipsticks across hospitals in the North Denmark Region. Furthermore, results will be compared to another Danish administrative healthcare region where dipsticks are still in use as well as urine culture data from the primary sector in the North Denmark Region.\n\nSince this is a registry-based observational study utilizing data from the electronic patient record system in the North Denmark Region, no direct contact will be made with participants.",[25,26,27,28,29,30,31],"Urinary Tract Infections","Diagnostic Techniques and Procedures","Point-of-Care Testing","Anti-Bacterial Agents","Registry","Clinical Decision-making","Urinalysis",[33,25,34,35,36,37],"Urine Dipstick De-implementation","Hospital","Registry-Based Study","Clinical Impact","urine dipsticks","NOT_YET_RECRUITING","2025-09-30",{"date":41,"type":42},"2025-10-01","ACTUAL",{"date":44,"type":20},"2025-12",{"date":46,"type":20},"2026-12",{"name":48,"class":49},"Jacob Bodilsen","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100474056","phase-4-aciclovir-versus-placebo-for-hsv-2-meningitis-100474056","NCT05452928","Aciclovir Versus Placebo for HSV-2 Meningitis","Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)","AMEN","Inclusion Criteria:\n\n* Adults ≥18 years of age admitted on suspicion of viral meningitis defined as:\n\n  1. A clinical presentation consistent with viral meningitis (e.g. headache, nuchal rigidity, photophobia, or fever) AND\n  2. Cerebrospinal fluid (CSF) pleocytosis (\\>4 leukocytes x 106\u002FL) AND\n  3. HSV-2 positive by PCR of the CSF\n  4. Glasgow Coma Scale score of 15 AND\n  5. Ability to absorb oral medications\n\nExclusion Criteria:\n\n* Patients fulfilling any of the following criteria will be excluded:\n\n  1. Encephalitis as defined by the International Encephalitis Consortium if diagnosed during standard care (see Glossary)20\n  2. Transverse myelitis as defined by the Transverse Myelitis Consortium Working Group if diagnosed during standard care (see Glossary)21\n  3. Severe immuno-compromise defined as an ongoing need for biological- or chemotherapy (e.g. natalizumab), prednisolone \\>20 mg\u002Fday for ≥14 days, uncontrolled HIV\u002FAIDS (see glossary), haematological malignancies, and organ transplant recipients14,18,22\n  4. Moderate to severe concomitant genital herpes requiring systemic aciclovir\n  5. Pregnancy (proven by positive urine or plasma human chorionic gonadotropin test in fertile women)\n  6. Hepatic impairment (aspartate aminotransferase or alanine aminotransferase levels \\>5 times the upper limit of normal)\n  7. Impaired renal function (estimated glomerular filtration rate \\\u003C25 mL\u002Fmin)\n  8. Intolerance to (val)aciclovir\n  9. Probenecid treatment\n  10. Systemic antiviral therapy with an antiherpetic effect for \\>24 hours\n  11. Previous enrolment into this trial",true,{"count":60,"type":20},150,"INTERVENTIONAL",[63],"PHASE4","To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation",[66,67],"Herpes Simplex 2","Meningitis, Viral",[69,70,71,72,73,74,75,76,77],"meningitis","HSV-2","Herpes simplex 2","viral meningitis","aseptic meningitis","acyclovir","valacyclovir","aciclovir","valaciclovir",{"date":41,"type":42},{"date":80,"type":20},"2026-06-01",{"date":82,"type":20},"2029-06-01",{"name":48,"class":49},""]